Journal article
2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)
JAMA : the journal of the American Medical Association, Vol.311(5), pp.507-520
02/05/2014
DOI: 10.1001/jama.2013.284427
PMID: 24352797
Abstract
Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately. Patients want to be assured that blood pressure (BP) treatment will reduce their disease burden, while clinicians want guidance on hypertension management using the best scientific evidence. This report takes a rigorous, evidence-based approach to recommend treatment thresholds, goals, and medications in the management of hypertension in adults. Evidence was drawn from randomized controlled trials, which represent the gold standard for determining efficacy and effectiveness. Evidence quality and recommendations were graded based on their effect on important outcomes.
There is strong evidence to support treating hypertensive persons aged 60 years or older to a BP goal of less than 150/90 mm Hg and hypertensive persons 30 through 59 years of age to a diastolic goal of less than 90 mm Hg; however, there is insufficient evidence in hypertensive persons younger than 60 years for a systolic goal, or in those younger than 30 years for a diastolic goal, so the panel recommends a BP of less than 140/90 mm Hg for those groups based on expert opinion. The same thresholds and goals are recommended for hypertensive adults with diabetes or nondiabetic chronic kidney disease (CKD) as for the general hypertensive population younger than 60 years. There is moderate evidence to support initiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, or thiazide-type diuretic in the nonblack hypertensive population, including those with diabetes. In the black hypertensive population, including those with diabetes, a calcium channel blocker or thiazide-type diuretic is recommended as initial therapy. There is moderate evidence to support initial or add-on antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to improve kidney outcomes.
Although this guideline provides evidence-based recommendations for the management of high BP and should meet the clinical needs of most patients, these recommendations are not a substitute for clinical judgment, and decisions about care must carefully consider and incorporate the clinical characteristics and circumstances of each individual patient.
Details
- Title: Subtitle
- 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)
- Creators
- Paul A. James - University of IowaSuzanne Oparil - University of Alabama at BirminghamBarry L. Carter - University of IowaWilliam C. Cushman - Memphis VA Medical CenterCheryl Dennison-Himmelfarb - Johns Hopkins UniversityJoel Handler - Kaiser Permanente Anaheim Medical CenterDaniel T. Lackland - Medical University of South CarolinaMichael L. LeFevre - University of MissouriThomas D. MacKenzie - Denver Health Medical CenterOlugbenga Ogedegbe - New York UniversitySidney C. Smith - University of North Carolina at Chapel HillLaura P. Svetkey - Duke UniversitySandra J. Taler - Mayo ClinicRaymond R. Townsend - University of PennsylvaniaJackson T. Wright - Case Western Reserve UniversityAndrew S. Narva - National Institute of Diabetes and Digestive and Kidney DiseasesEduardo Ortiz - National Heart Lung and Blood Institute
- Resource Type
- Journal article
- Publication Details
- JAMA : the journal of the American Medical Association, Vol.311(5), pp.507-520
- DOI
- 10.1001/jama.2013.284427
- PMID
- 24352797
- NLM abbreviation
- JAMA
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- Number of pages
- 14
- Grant note
- AstraZeneca Novartis Medtronic National Center for Advancing Translational Sciences (http://data.elsevier.com/vocabulary/SciValFunders/100006108) UL1TR000439 / National Center for Advancing Translational Sciences (http://data.elsevier.com/vocabulary/SciValFunders/100006108)
- Language
- English
- Date published
- 02/05/2014
- Academic Unit
- Family and Community Medicine; Pharmacy Practice and Science
- Record Identifier
- 9985217029802771
Metrics
2 Record Views